Antibacterial drugs can be produced from bacteria or molds, or they can be created from scratch. These medications destroy or slow down growth of bacteria. Antibacterial drugs are used in the treatment of urinary infections caused by E. coli, S. aureus, Streptococcus pyogenes and other bacterial infections. Influenza is a contagious respiratory infection caused due to influenza virus. Antibacterial drugs play a major role in advanced healthcare, as they are majorly used in treatment and prevention of infectious diseases such as Influenza (flu), cold. Antibacterial drugs act by destroying or inhibiting microbial growth. Antibacterial drugs are used in treatment of infections caused by various bacteria such as Escherichia coli, Klebsiella pneumonia, and others. Moreover, increasing incidences of infectious diseases such as tuberculosis, hepatitis B, leprosy, typhoid, malaria, Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) and others is expected to drive market growth.
Global antibacterial drugs market is estimated to be valued at US$ 44,612.2 Mn in 2022 and is expected to exhibit a CAGR of 4.3% over the forecast period (2022-2030).
Figure 1: Global Antibacterial Drugs Market Share (%) Analysis, By Drug Class, 2022
High prevalence of bacterial tuberculosis, chlamydia, bacterial vaginosis, syphilis, and others globally is expected to drive global antibacterial drugs market growth over the forecast period.
High prevalence of bacterial tuberculosis, chlamydia, bacterial vaginosis, syphilis, and others, globally is expected to be the major factor driving growth of the antibacterial drugs market over the forecast period. According to the data of World Health Organization (WHO) in October 2021, a total of 1.5 million people died from Tuberculosis in 2020 (including 214 000 people with HIV). Worldwide, TB is the 13th leading cause of death and the second leading infectious disease after COVID-19 (above HIV/AIDS).
|Base Year:||2021||Market Size in 2022:||
US$ 44,612.2 Mn
|Historical Data for:||2017 to 2029||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||4.3%||2030 Value Projection:||
US$ 65,444.5 Mn
Spero Therapeutics, Allecra Therapeutics, R-Pharm Group, Melinta Therapeutics LLC, MicuRx, TenNor Therapeutics Ltd, Venatorx Pharmaceuticals, Inc., GlaxoSmithKline plc., AstraZeneca , Bayer AG , Johnson & Johnson, Bristol-Myers Squibb Company, Merck & Co., Inc., Eli Lilly and Company, AbbVie Inc., Novartis AG, Pfizer Inc., and Sanofi
|Restraints & Challenges:||
Increasing product approvals from regulatory bodies is expected to drive global antibacterial drugs market growth over the forecast period.
Antibacterial drugs market is expected to witness significant growth over the forecast period, owing to increasing focus of market players on gaining product approvals from regulatory bodies. For instance, in June 2021, Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved the company’s supplemental new drug application (sNDA) for the oral-only dosing regimen of NUZYRA for the treatment of adults with community-acquired bacterial pneumonia (CABP)
Global Antibacterial Drugs Market- Impact of the Coronavirus (COVID-19) Pandemic
Demand for antibacterial drugs is expected to increase during the pandemic, owing to high usage of antibiotics during COVID-19 treatment. For instance, according to an article published by The Journal of Antimicrobial Chemotherapy in August 2020, it has been reported that around 15% of COVID-19 patients in Wuhan, China were subjected to antifungal treatment, while around 71% received antibiotic treatment, 25% of whom were completely treated with a single antibiotic, and 45% with combination antibiotic therapy. The antibiotics used included, tigecycline (against methicillin-resistant Staphylococcus aureus (MRSA)), quinolones, cephalosporin, carbapenems, and linezolid.
Global Antibacterial Drugs Market– Restraints
High cost of vaccine development is expected to hinder growth of market over the forecast period. For instance, on June 22, 2021, an article published in BMJ, a scientific journal stated about high costing of vaccine. The Centers for Disease Control and Prevention (CDC) purchased bulk vaccine through agreements for the 2020-21 flu season, the CDC purchased seven million doses directly from manufacturers for US$ 100 Mn each a higher price than it had in previous year 2020.
Global Antibacterial Drugs Market– Regional Analysis
On the basis of region, the global antibacterial drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Among regions, North America is expected to hold a dominant position in market during the forecast period, owing to the increasing number of regulatory approvals for antibacterial drugs, which is expected to boost growth of the global antibacterial drugs market. For instance, In March 2021, Melinta Therapeutics LLC, a U.S. based biopharmaceutical company had announced that it had received the U.S. Food and Drug Administration (FDA) approval for its new drug KIMYRSA (oritavancin), a lipoglycopeptide antibiotic indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI).
Figure 2: Global Antibacterial Drugs Market Value (US$ Mn), by Region, 2022
Global Antibacterial Drugs Market– Competitive Landscape
Major players operating in the global antibacterial drugs market include Spero Therapeutics, Allecra Therapeutics, R-Pharm Group, Melinta Therapeutics LLC, MicuRx, TenNor Therapeutics Ltd, Venatorx Pharmaceuticals, Inc., GlaxoSmithKline plc. AstraZeneca , Bayer AG , Johnson & Johnson, Bristol-Myers Squibb Company, Merck & Co., Inc., Eli Lilly and Company, AbbVie Inc., Novartis AG, Pfizer Inc., and Sanofi
Antibacterial drugs are derived from bacteria or molds. These antibacterial drugs are synthesized from simple molecules to form complex molecules. Antibiotics work in a variety of ways, such as inhibiting cell wall production, increasing cell membrane permeability, and interfering with protein synthesis, nucleic acid metabolism, and other metabolic processes by inhibiting cell wall production, nucleic acid metabolism, and other metabolic processes. Antibiotics can raise or lower the serum levels of other medications by increasing or decreasing their metabolism. The most clinically important interactions involve drugs with a low therapeutic ratio. Other drugs can also increase or decrease levels of antibiotics. Antibacterial drugs include a range of powerful drugs such as phenoxymethylpenicillin, penicillin V. and are used to treat diseases caused by bacteria. Antibiotics cannot treat viral infections, such as cold, flu, and most coughs.
Increasing inorganic activities such as partnerships among market players is expected to drive the global antibacterial drugs market growth over the forecast period. For instance, In March 2021, Cipla Therapeutics, a division of Cipla USA Inc., an affiliate of Cipla Limited, and SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on health security market announced a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against bio threats such as tuberculosis and others.
Furthermore, In April 2017, R-Pharm Group, a specialty pharmaceutical company had announced that it entered into a strategic partnership with Mitsui & Co., Ltd., a Japan-based general trading company which acquired around 10% of R-Pharm Group’s shares. This partnership would help R-Pharm Group expand its business presence in Japan
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.